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Abstract. We have performed a retrospective review ofthe incidence and etiologies of acute renal failure (ARF) in 
105 adult patients receiving liver transplants. The prevalence of chronic renal failure was also determined. ARF 
occurred in 94.2% of these patients. Acute tubular necrosis was the leading cause of ARF and was associated with the 
highest mortality. Factors associated with increased mortality included: (I) peak serum creatinine >3 mg/dl. (2) 
multiple liver transplants and (3) the need for dialysis. Pretransplant renal failure did not increase mortality. Chronic 
renal failure developed in 83% of patients at latest follow-up (mean: 30.5 ± 7.9 months). 
Introduction 
Since the introduction of ciclosporin, liver transplan-
tation has become an effective treatment for end-stage 
liver disease with a I-year survival now approximating 
10% [1-3]. In the patient with severe liver disease, gas-
trointestinal hemorrhage. the administration of poten-
tially nephrotoxic agents and a number of other insults 
may predispose to the development of acute renal failure 
(ARF) [4]. Hyperbilirubinemia, an ubiquitous finding in 
liver failure, may be directly nephrotoxic and may com-
plicate matters by rendering patients exposed to other 
noxious influences more susceptible to the development 
of ARF (5). Hypotension from massive blood loss compli-
cated by the vascular instability, which often accompan-
ies end-stage liver disease. provides a well-recognized 
clinical environment in which ischem'ic renal damage 
often occurs [6]. Postoperatively. infection, rejection, and 
volume overload or depletion in addition to ciclosporin 
toxicity make this period particularly troublesome with 
respect to the maintenance of normal renal function. 
Long-term patients require immunosuppression with 
ciclosporin to preserve liver function, but face the possi-
bility of developing progressive renal insufficiency due 
to the nephrotoxicity associated with the chronic use of 
this drug [7,8). 
Although renal function is, therefore, at jeopardy in 
each phase of liver transplantation, very little informa-
tion is available which precisely identifies the etiology of 
ARF postoperatively or the contribution of ciclosporin to 
impaired renal function chronically. Most studies have 
been limited by small numbers of patients, and no study 
has specifically attempted to determine the precise etiol-
ogy of ARF during the peri-operative period in adult 
patients. Likewise, although data have accumulated re-
garding the nephrotoxicity of cic1osporin in the heart 
transplant setting [7,8], a paucity of information is avail-
able on the renal consequences of administering this drug 
on a chronic basis after liver transplantation. Transplan-
tation of large numbers of patients with end-stage liver 
disease at the University of Pittsburgh has provided us 
with a unique opportunity to more fully characterize 
renal failure in this setting. Therefore, we have reviewed 
the charts of adult liver transplant patients during the 
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perioperative period (0 evaluate the incidence, etiologies, 
and impact on survival of the development of ARF. In 
addition, we obtained long-term follow-up data on these 
patients to determine the prevalence of chronic renal 
failure after liver transplantation. 
Patients and Methods 
We reviewed the chans of 189 consecutive adult patients receiv-
ing orthotopic liver transplants at the University of Pittsburgh 
Health Center between December 1983 and Augustl98S. Sufficient 
information was available on lOS patients to allow their inclusion. 
Patients were excluded forthe following reasons: (I) a portion of the 
charts was unavailable for review or, (2) the patient died within 72 h 
of transplantation. Each chart was reviewed by one of the authors 
for the occurrence and etiology of ARF in the postoperative period. 
The surgical procedures and immunosuppression schedules have 
been published elsewhere [2]. All patients were treated initially with 
prednisone 200 mg/day and ciclosporin 17.S mg/kg/day. Both 
drugs were subsequently tapered to the minimum dose required to 
maintain graft function. Ciclosporin was measured by radioimmu-
noassay kit (Sandoz Laboratories). 
Renal function was monitored by daily serum creatinine and 
BUN. Graft function was monitored with serial measurements of 
serum bilirubin, SGOT and alkaline phosphatase. Liver scans and 
nonenhanced CAT scans were obtained as clinically needed. 
EtiologiC Definitions 
ARF was defined as a SO% or greater increase in postoperative 
serum creatinine (SCr) compared to pretransplant values. Pretrans-
plant SCr was obtained within 24 h prior to surgery in all cases. 
When more than one potential insult was present, the insult consid-
ered to be the primary cause was used. 
The term ischemic acute tubular necrosis (ATN) was applied if a 
50% or greater rise in SCr occurred within 24 h after an identifiable 
hypotensive period. The urinalysis was required to be consistent 
with the diagnosis of ATN. 
Aminoglycoside-induccd ATN was defined as ARF occurring 
after at least 7 days of aminoglycoside administration. Trough levels 
were usually elevated and urinalyses were consistent with A TN. 
Severe volume depletion as the cause for ATN was determined 
to be the etiology of ARF when the central venous pressure was 
severely depressed for prolonged periods of time and weight loss 
was documented. The SCr, which had risen initially sufficiently to 
satisfy the criteria for ARF. did not decline after volume repletion or 
reduction of ciclosporin dosage. Urinalyses were consistant with 
ATN. 
Cic1osporin toxicity was determined to be the sole etiology of 
ARF if SCr fell to baseline following a reduction in ciclosporin 
dosage in the absence of other corrective measures. 
Hepatorenal syndrome (HRS) was considered to be present 
prior to transplantation in the absence of other causes of ARF when 
the following criteria were met: (I) severe liver failure at the time of 
liver transplantation, (2) urinary sodium < 10 mEq/l. (3) absence of 
detectable volume depletion. and (4) urinary osmolality of 400 
mosm/kg or greater. In addition, these patients were required to 
have oliguria and a slowly progressive rise in SCr. 
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Allergic interstitial nephritis was diagnosed in I patient taking 
trimethoprim-sulfa. Eosinophilia. skin rash and eosinophiluria 
were present and SCr fell to baseline after discontinuation of the 
drug. 
Prerenal azotemia was diagnosed in patients with evidence for 
volume depletion (weight loss. low central venous pressures, etc.) in 
which SCr returned to baseline values after volume repletion. Uri-
nalyses were required to have a benign appearance with high speci-
fic gravity. Although most would not apply the term ARF to these 
patients in clinical practice. a significant rise in SCr is often called 
ARF[91· 
Statistical Ana(rses 
All values presented are expressed as means ± SD. Student's t 
test or analysis of variance were used where appropriate to deter-
mine significant differences between means. Contingency table 
analyses were also employed to analyze some of the data. Multivar-
iant analysis was performed using discriminant analysis techniques 
(10]. Life table analyses were carried out using standard methods [II]. 
Results 
Demographic Data 
Of the 105 patients included in this review, 43 (41%) 
were male and 62 (59%) were female. The mean age of all 
patients was 39.2 ±9.9 years with ages ranging between 18 
and 57 years. There was no significant differences in age 
between men and women. The commonest causes oflifer 
failure in this group of 105 patients with ARF were: (I) 
primary biliary cirrhosis (30 patients, 28.6%), (2) scle-
rosing cholangitis (27 patients, 25.7%) and (3) chronic 
active hepatitis (23 patients, 21.9%). Other diagnoses in-
cluded: Sudd-Chiari syndrome, Wilson's disease, gold 
hepatotoxicity, hepatoma, alcoholic liver disease, a-I-an-
titrypsin disease. non-A. non-S hepatitis, hemochroma-
tosis and polycystic liver and kidney disease. The inci-
dences of these latter diseases varied between 1 and 5.7%. 
ARF during the Perioperar;ve Period 
During the postoperative period, 99 (94.3%) of the 105 
patients developed ARF. The mean pretransplant SCr in 
patients developing renal failure was 0.92 ± 0.62 mgl dl 
·and peak SCrwas 2.71 ± 1.4mg/dl (p < 0.0001). There was 
no significant difference between pretransplant SCr in 
patients who developed ARF and those who did not. 
Renal failure was mild (peak Ser < 1 mg/dl) in 36 pa-
tients (36.4%), moderate in 24 patients (24.2%, peak SCr 
2-3 mg/dl) and severe in 39 patients (39.4%, peak SCr 
3-7.7 mg/dl). Ten of the patients in the latter group 
required dialysis. 
The etiologies of ARF are listed in table 1. Ischemic 
A TN was the leading cause of ARF followed by ciclo-
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Table 1. Etiology of ARF 
Etiology 
Ischemic ATN 
Aminoglycoside ATN 
Volume depletion-induced A TN 
Cic\osporine toxicity 
Prerenal azotemia 
HRS 
Allergic interstitial nephritis 
Unknown 
NoARF 
Total 
Figures in parentheses represent percentage. 
sporin toxicity. ATN resulted in nearly half of the cases of 
ARF (44.8%). Patients without a specific cause for ARF 
comprised 21.9% of patients but developed only a mild 
increase in SCr. One of the patients with aminoglycoside-
induced A TN received both liver and kidney transplants 
for polycystic liver and kidney disease. For all patients, 
neither the mean nor peak cyclosporin levels correlated 
with the occurrence of ARF of peak Ser. Ciclosporin 
toxicity was probably underdiagnosed in this study since 
many of the patients not so classified experienced a fall in 
SCr when the dosage was decreased. Hepatorenal syn-
drome was diagnosed prior to transplantation; SCr con-
tinued to rise postoperatively and began to fall only after 
8.0 ± 4.1 days. Oliguria was predominantly found in pa-
tients with ischemic A TN (32/34, 94%) and volume de-
pletion-induced ATN. Oliguria was much less common 
in the other groups: aminoglycoside ATN (2/11, J8.2%), 
HRS (214, 50%), and allergic interstitial nephritis (Ill, 
100%). The remaining patients were nonoliguric. 
Mortality 
Twenty patients died during the initial transplant ad-
mission. Relevant data are provided in tables I and 2. 
Autopsies were available on 13 of these patients. Histo-
logic examination of the kidneys revealed vacuolization 
of tubular cells in all except 2 patients. Tubular cell 
dropout and mitotic figures were found in all patients 
with ATN. There was no evidence of interstitial fibrosis 
in any case. Three patients with A TN and sepsis were 
found to have small renal infarctions. Gram-negative 
sepsis was the immediate cause of death in 12 of the 20 
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Number of patients SCr. mg/dl Deaths 
pre-Tx peak 
34 (32.4) \.05+0.78 3.27±1.I3 14 (41.2) 
II (10.5) 1.15+0.73 3.97 + 2.0 3 (27.3) 
2 ( 1.9) 0.75±0.21 2.55+ 1.6 I (SO) 
17(16.2) 0.78±0.27 2.8± 1.4 o 
7 (6.7) 0.74±0.28 \.56+0.8 o 
4 (3.8) 1.9±0.4 3.5+2.1 1(25) 
I (I) 0.9 5.1 o 
23 (21.9) 0.74±3.1 \.99±0.79 1(4.4) 
6 (5.7) 0.67 +0.34 1.18 +0.29 o 
105 (100) 20 (19) 
Table 2. Causes of death in patients with ARF following liver 
transplantation 
Causes of death 
Sepsis (12112)" 
Respiratory failure (aspiration)· 
Subarachnoid hemorrhage 
Rejection alone 
Pulmonary hemorrhage· 
Pulmonarv embolus 
Ruptured hepatic anery anastomosis' 
Cardiac tamponade 
Gastrointestinal hemorrhage· 
• Liver failure due to rejection contributed to death. 
Number 
of patients 
12 
patients but was also a major contributor to the deaths of 
4 additional patients. The latter patients died of (I) a 
ruptured aortic anastomosis, (2) subarachnoid hemor-
rhage, (3) liver failure and (4) pulmonary hemorrhage. 
Although liver failure was the proximate cause of death 
in only 1 patient in this series. liver failure due to trans-
plant rejection was a major complication in 16 others. The 
mean total bilirubin when Ser was at peak in survivors 
and nonsurvivors was 5.6 ± 5.7 and 11.1 ± 6.6 mg/dl. re-
spectively (p ... 0.0041). There was no difference in pre-
transplant total bilirubin between survivors and nonsur-
vivors. 
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Fic. I. Pretransplant Ser values plotted versus percent survival 
in liver transplant recipients. 
Discriminant analysis was performed. searching for 
the combination of factors which would best predict 
survival and the need for dialysis. The following var-
iables were considered: (I) age, (2) sex, (3) pretransplant 
Ser, (4) peak Ser, (5) pretransplant BUN, (6) peak BUN, 
(7) pretransplant bilirubin, (8) bilirubin at peak Ser, (9) 
mean ciclosporin level prior to rise in Ser, (10) peak 
ciclosporin level prior to the initial rise in Ser, (ll) dura-
tion of hospitalization, (12) etiology of liver disease, (13) 
etiology of ARF and (14) the need for dialysis. Only two 
factors, when combined, increased the accuracy of pre-
dicting patient survival. They were (I) the need for dialy-
sis and (2) the etiology of ARF. Peak Ser was found to be 
the only important variable in predicting the need for 
dialysis. The influence of these variables and those which 
did not affect survival are considered below. 
Pretransplant Renal Function and Perioperative 
Survival 
Pretransplant Ser had no significant influence upon 
peri operative mortality (figure I). Sixty· five of eighty-
four patients with pretransplant Ser less than l.l mg/dl 
survived, as did IS ofl6 patients with values 1.1-2.5 mgldl 
and 5 of 5 patients with values greater than 2.5 mgl dl. 
Although patients with the most severe pretransplant 
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Fia. 2. Percent survival in patients with mild, moderate, and 
severe ARF. Patients are categorized to the level of their peak Ser 
values. 
renal impairment appeared to have improved survival, 
there was no significant difference as a function of pre· 
transplant Ser (p - 0.1677). 
Degree of Renal Failure as a Predictor of Survival 
Figure 2 displays the relationship of peak Ser to 
mortality. Among the 33 patients with a peak level < 1.7 
mgl dl, I patient expired, yielding a mortality rate for that 
group of 3%. For patients with a peak Ser of 1. 7 -3 mgl dl, 
2 of 30 patients expired (mortality rate of 6.7%). For 
patients with peak Ser between 3 and 4.3 mgl dl, mortal-
ity was 33.3% with 9 of 27 patients dying. Of the lO 
patients with peak creatinine between 4.3 and 5.6 mgldl, 
4 (40%) expired. Two of the three patients with peak ser 
between 5.6 and 6.9 mg/d1 expired and both patients with 
peak creatinine of 6.9 mg/dl or greater died. A Ser 
greater than 3.0 mg/dl. therefore. carried a significant 
risk of death (p < 0.00(1). 
Etiology of ARF and Survival 
Survival during the initial transplant admission was 
significantly influenced by the etiologic classification of 
renal failure (table I. p-0.OO85). Patients with hypoten-
sion·induced ATN experienced the greatest mortality 
with 14 of 34 patients (41.2%) expiring during the initial 
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Fia. 3. Mean SCr values in the pretrans-
plant period. at discharge. and at latest 
follow-up for patients categorized accord-
ing to the etiology of their ARF. ISC-
Ischemic A TN; AM 1- aminoglycoside-
induced ATN: VO - volume depletion-in-
duced ATN: CYA-ciclosporin toxicity; 
PR-prerenal azotemia; NARF-no 
ARF; UNK-unknown; HPR-HRS: 
AIN - allergic interstitial nephritis. 
transplant admission. Three of eleven patients (27.3%) 
with aminoglycoside-induced ATN died as did 1 of 2 
patients with volume depletion-induced ATN. The over-
all mortality for patients with ATN was 39%. 
The remaining etiologic groups demonstrated rela-
tively low mortality rates. Within this group, patients with 
HRS had the greatest mortality with I of 4 patients (2S%) 
expiring. Patients in the unknown group experienced low 
mortality with only one death in 23 patients (4.4%). The 
remaining etiologic groups experienced no deaths. 
Dialysis as a Determinant 0/ Perioperative Survival 
The most significant predictor of death during the 
perioperative period was the need for dialysis. ARF re-
quiring hemodialysis occurred in 10 patients or 10.1% of 
those with ARF. Five (14.7%) of the 34 patients with 
hypotension-induced ATN were dialyzed, as were 2 
(18.2%) of the II with aminoglycoside-induced ATN and I 
of the 2 patients with volume depletion-induced ATN. 
One of the two remaining patients had HRS and the 
etiology of the ARF in the other patient was unknown. Of 
the 10 patients who were dialyzed, only I survived the 
initial transplant admission (i.e., 90% mortality rate). Ten 
(11.2%) of the eighty-nine patients who were not dialyzed 
died. Of the 20 patients who did not survive, 10 were 
dialyzed. 
Number o/Transplants as a Determinant 0/ Survival 
Multiple liver transplants were performed in 20 of the 
lOS patients. Mortality was directly related to the number 
of liver transplants. For solitary transplants, the mortality 
rate was 9.4% (8/8S), for two transplants: S6.3% (9/16), 
and for three transplants: 7S% (3/4), P < O.oooS. The need 
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for dialysis was also directly related to the number of 
transplants: 1.2% (1I8S) for solitary transplants, 31.3% 
(S/16) for two and 7S% (3/4) for three transplants. 
p<O.OOOI. 
Renal Function during Long-Term Follow-up 
Eighty-five patients survived the initial admission for 
liver transplantation. Mean follow-up in the survivors 
was 30.4±9.9 months. Mean Ser for all survivors was 
1.94±0.94 mg/d!. Twelve patients died during the fol· 
low-up period and no patient was lost to follow-up. The 
causes of death included liver failure [81 metastatic car· 
cinoma [I], probable myocardial infarction [I], pulmonary 
embolus [I] and unknown in I patient. 
Mean pretransplant. discharge, and latest follow-up 
values of Ser for all survivors by etiology of ARF are 
presented in figure 3. Mean Ser at latest follow-up was 
greater than pretransplant and discharge values in all 
etiologic groups except HRS. Renal function at latest 
follow-up was relatively well preserved in patients with 
prerenal azotemia (1.7 ± 0.3), HRS (l.S3±0.S) and no 
ARF (1.38 ± 0.26) during the postoperative period. 
Patients with an unknown etiology of ARF during the 
postoperative period developed moderate renal insuffi· 
ciency with latest follow-up Ser of 2.24± 1.7S mg/dJ. 
One patient, a 38-year-old male with alcoholic cirrhosis, 
has started chronic hemodialysis 18 months after trans-
plantation. Since a renal biopsy was not performed. the 
precise etiology of his progressive chronic renal failure 
could not be documented. 
Serum creatinine varied at each routine monthly clinic 
visit for all patients but tended to fall when ciclosporin 
dosage was reduced. Neither the daily ciclosporin dose at 
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latest follow-up (3S5 ± 172.7 mglday, S.5±3.3 mglkgl 
day) nor the absolute ciclosporin level (mean: 476.9 ± 222 
ngl ml) correlated with SCr at latest follow-up. There was 
no significant difference in mean ciclosporin dosage be-
tween etiologic groups either as regards liver failure or 
ARF. 
At latest follow-up, 14 of the 8S surviving patients 
(16.5%) retained normal renal function defined as SCr 
less than 1.7 mgldl. Figure 4 presents the life table anal-
ysis for the development of chronic renal failure. The 
greatest decline in renal function occurred during the 
first 18 months after transplantation. At 6 months, I year 
and 18 months after transplantation, the probability of 
retaining normal renal function was 64.3, 48.5 and 39.7%, 
respectively. By the 39th month it was 22.67%. 
Hypertension and hyperkalemia were common com-
plications during the follow-up period. We could docu-
ment a prior history of hypertension in 10 of the 85 
patients surviving the initial admission for transplanta-
tion. During the follow-up period, 50 developed hyper-
tension for the first time. Spontaneous hyperkalemia 
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occured in 23 patients at some time during the follow-up 
period. Thirteen were taking a p-blocker or angiotensin-
converting enzyme inhibitor for hypertension. However, 
the hyperkalemia was probably not due to chronic renal 
failure per se since mean SCr values of patients with and 
without hyperkalemia were 2.04 ± 1.39 and 1.84 ± 0.61 
mgl dl, respectively (p - 0.42). 
Discussion 
The major findings obtained in this study provide the 
following new information (I) ARF is a common compli-
cation of orthotopic liver transplantation. (2) The etiol-
ogy of ARF is a major determinant of patient survival. 
The commonest and most serious cause of ARF is A TN 
related to prolonged ischemia associated with sepsis. (3) 
Pretransplant renal impairment did not result in greater 
risk of death. (4) Renal failure severe enough to require 
dialysis was almost universally fatal. (5) Chronic renal 
failure, probably due to ciclosporin, is also a common 
complication. 
Only one previous study, by Ellis et al. [12] in children, 
has systematically determined the etiology of ARF after 
liver transplantation. These workers found that, of the 19 
patients studied, HRS (7 patients) was the most common 
cause of ARF. We found that HRS was much less com-
mon in the adults (3.8%) and that ATN, of all causes, 
comprised fully 50% of patients with ARF. 
Previous information on the incidence of ARF in the 
adult during liver transplantation derives from a limited 
number of relative small studies [12-17]. The incidence 
has been reported to be as low as 21% and as high as 73%. 
The major cause of these differing incidence figures 
appears to be variations in the criteria for ARF utilized in 
the various studies. Iwatsuki et al. [13] reported upon the 
incidence of ARF in 13S patients: 71 adults and 64 chil-
dren. Acute renal failure was defined as the development 
of a BUN of 50 mgl dl or a SCr of 2 mgl dl. ARF occurred 
in 15 of 71 adults (21%) and 14 of 64 children (22%). 
Powell-Jackson et al. (14) reported a 53% incidence in 27 
patients, using a SCr value exceeding 200 ~M (2.3 mgl dl) 
as their criterion. In a preliminary communication, Dan-
ovitch et a1. [IS] reported an incidence of 66% for adults 
(37 children, 36 adults), using a 100% rise in Ser over 
pretransplant values as the basis for the diagnosis. Willi-
ams et al. [16] reported that 21 of 29 patients (73%) devel-
oped either acute or chronic renal failure defined as a 
sEFl~ increase in SCr over the upper limits of normal for 
their laboratory. 
Renal Failure in Liver Transplantation 
In our series of patients, mortality was related to peak 
Ser, the need for dialysis, and the number of liver trans-
plants. Although none of the previous studies of ARF in 
liver transplantation commented upon the influence of 
increasing numbers of transplants on survival, there is 
evidence which verifies this association [17, 18]. 
Most previous studies confirm our observation that 
the need for dialysis is a grave prognostic indicator. Ellis 
et a1. [12] further suggested that the dialysis procedure 
itself may increase the risk of death due to heparin-re-
lated hemorrhagic complications and the risk of hypo ten-
sion. We could not verify this thesis since only I patient in 
our series experienced massive hemorrhage shortly after 
dialysis, which was due to rupture of the hepatic artery 
anastomotic site. This patient received no heparin during 
dialysis. None of the studies of ARF in liver transplanta-
tion has demonstrated a beneficial effect of dialysis on 
survival [12-15], nor is there evidence that early and ag-
gressive dialysis in any other clinical setting is effective in 
reducing mortality [19, 20]. 
There is growing evidence that ciclosporin given 
chronically results in chronic renal failure [7, 8, 21-23]. 
While the pathogenesis ofthis form of nephrotoxicity is 
not well understood, the noxious effects of ciclosporin 
form a spectrum from an acute reduction in glomerular 
filtration rate which is usually reversible, to a chronic 
irreversible form characterized by interstitial fibrosis [7, 
22, 23]. Increased renal vascular resistance may play a 
major role in the acute form and alterations in the levels 
of vasoconstrictor prostaglandins may have pathophys-
iologic importance [7, 24-26]. 
Hypertension and hyperkalemia were also common 
complications of chronic ciclosporin therapy, as has been 
reported elsewhere [7, 8, 24]. While the etiology of the 
hypertension in these patients is not clear, it seems most 
likely to be the result of the drug, although it may be 
related to the alterations in renal function. Furthermore, 
the mechanism by which ciclosporin causes hypertension 
is unclear but could, in part, be the result of a drug-in-
duced increase in peripheral vascular resistance [7]. 
There is evidence that the suppressed renin and aldoste-
rone secretion rates often found in patients taking ciclo-
sporln may represent a direct effect of the drug [27]. 
Liver transplantation with ciclosporin has clearly be-
come the only method of preserving the lives of many 
desperately ill patients with end-stage liver disease. The 
very success of ciclosporin in preventing rejection and 
the deaths of these patients has allowed us to consider the 
effects of this drug over long periods of time. Strategies 
for reducing the chronic nephrotoxicity of ciclosporin 
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are currently in evolution and the management of the 
patients in this study reflects the maturation of knowl-
edge that is being acquired in the use of this agent. 
Methods currently being practiced include: (1) at-
tempts at reducing ciclosporin dosage to the absolute 
minimum required to prevent rejection while using only 
ciclosporine and prednisone, (2) reducing ciclosporin 
dosage by adding azathioprine and (3) developing new 
immunosuppressant agents without nephrotoxicity. 
Iwatsuki et a1. [13] and KIintmalm et a1. [28] have both 
suggested that the high incidence of chronic renal failure 
during the first 12-18 months after transplantation is 
directly related to high ciclosporine doses using during 
the early posttransplantation period. The relative reduc-
tion in the incidence of new patients developing chronic 
renal failure after 20 months in our study would support 
this hypothesis. The addition of azathioprine and subse-
quent reduction in ciclosporin was instituted in some 
patients at this center during this study and may further 
preserve renal function. Finally, new agents under inves-
tigation, used in combination with ciclosporin or alone, 
may further reduce the risk of acute and chronic ciclo-
sporin nephrotoxicity [29]. 
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